Immune checkpoint inhibitors, targeting CTLA-4 and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in malignant tumors [33]. This evidence concerns the gene CD274 and cancer.